SCHEMBL4428890

SCHEMBL4428890

CCOCC1CCCN(C(=O)OC(C)(C)C)C1

nearest known ligand 0.60

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.51
ALDH1A1 P00352 1/20 0.51
MAPT P10636 1/20 0.51
KMT2A Q03164 1/20 0.51
SCN9A Q15858 1/20 0.48
GLS O94925 2/20 0.47
HPGD P15428 1/20 0.46
BACE1 P56817 2/20 0.45
ACKR3 P25106 1/20 0.45
CTSD P07339 1/20 0.45
FEN1 P39748 2/20 0.43
NR1H2 P55055 1/20 0.43
ALOX5AP P20292 1/20 0.43
KDM1A O60341 1/20 0.43
CHEK2 O96017 1/20 0.43
CYP2C9 P11712 1/20 0.41
EPHX1 P07099 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13162270 1.00 MEN1 (0.51) MEN1ALDH1A1MAPTKMT2ASCN9A
SCHEMBL13634196 1.00 MEN1 (0.51) MEN1ALDH1A1MAPTKMT2ASCN9A
SCHEMBL5235715 0.93 MEN1 (0.48) MEN1ALDH1A1MAPTKMT2ASCN9A
SCHEMBL22650349 0.92 NR1H2 (0.46) MEN1ALDH1A1MAPTKMT2AHPGD
SCHEMBL8574578 0.88 MEN1 (0.48) MEN1ALDH1A1MAPTKMT2ASCN9A
SCHEMBL695894 0.87 MEN1 (0.54) MEN1ALDH1A1MAPTKMT2ASCN9A
SCHEMBL22290470 0.87 MEN1 (0.54) MEN1ALDH1A1MAPTKMT2ASCN9A
SCHEMBL772145 0.87 MEN1 (0.54) MEN1ALDH1A1MAPTKMT2ASCN9A
SCHEMBL8240271 0.86 MEN1 (0.49) MEN1ALDH1A1MAPTKMT2ASCN9A
SCHEMBL5235533 0.86 MEN1 (0.49) MEN1ALDH1A1MAPTKMT2ASCN9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2206707-A1 AZOLECARBOXAMIDE COMPOUND OR SALT THEREOF Astellas Pharma Inc. (JP) 2010-07-14 EP disclosed
EP-2024359-A1 COMPOUNDS THAT ARE AGONISTS OF MUSCARINIC RECEPTORS AND THAT MAY BE EFFECTIVE IN TREATING PAIN, ALZHEIMER'S DECEASE AND/OR SCHIZOPHRENIA AstraZeneca AB (SE) 2009-02-18 EP disclosed
WO-2007126362-A1 COMPOUNDS THAT ARE AGONISTS OF MUSCARINIC RECEPTORS AND THAT MAY BE EFFECTIVE IN TREATING PAIN, ALZHEIMER'S DISEASE AND/OR SCHIZOPHRENIA ASTRAZENECA AB (SE) 2007-11-08 WO disclosed
WO-2007126362-A1 COMPOUNDS THAT ARE AGONISTS OF MUSCARINIC RECEPTORS AND THAT MAY BE EFFECTIVE IN TREATING PAIN, ALZHEIMER'S DISEASE AND/OR SCHIZOPHRENIA ASTRAZENECA AB (SE) 2007-11-08 WO disclosed
US-20070259888-A1 Novel Compounds ASTRAZENECA AB (SE) 2007-11-08 US disclosed
US-20070259888-A1 Novel Compounds ASTRAZENECA AB (SE) 2007-11-08 US disclosed
US-20070259888-A1 Novel Compounds ASTRAZENECA AB (SE) 2007-11-08 US disclosed
EP-1764367-A1 THIENOPYRIDINE DERIVATIVES Sankyo Company, Limited (JP) 2007-03-21 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070259888-A1 Novel Compounds OPRL1, OPRM1, SIGMAR1 MEN1 2497/4885ALDH1A1 1047/4885MAPT 2686/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.